A detailed history of Advance Capital Management, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Advance Capital Management, Inc. holds 3,252 shares of ABBV stock, worth $582,758. This represents 0.04% of its overall portfolio holdings.

Number of Shares
3,252
Previous 2,739 18.73%
Holding current value
$582,758
Previous $469,000 36.89%
% of portfolio
0.04%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$163.84 - $199.33 $84,049 - $102,256
513 Added 18.73%
3,252 $642,000
Q2 2024

Jul 08, 2024

SELL
$154.79 - $180.76 $25,230 - $29,463
-163 Reduced 5.62%
2,739 $469,000
Q1 2024

Apr 04, 2024

BUY
$159.82 - $182.1 $7,671 - $8,740
48 Added 1.68%
2,902 $528,000
Q4 2023

Jan 10, 2024

SELL
$137.6 - $154.97 $19,401 - $21,850
-141 Reduced 4.71%
2,854 $442,000
Q3 2023

Oct 13, 2023

BUY
$133.59 - $154.65 $53,836 - $62,323
403 Added 15.55%
2,995 $446,000
Q2 2023

Jul 03, 2023

BUY
$132.51 - $164.9 $107,995 - $134,393
815 Added 45.86%
2,592 $349,000
Q1 2023

Apr 04, 2023

BUY
$144.61 - $166.54 $144 - $166
1 Added 0.06%
1,777 $283,000
Q4 2022

Feb 08, 2023

SELL
$138.31 - $165.87 $19,363 - $23,221
-140 Reduced 7.31%
1,776 $287,000
Q3 2022

Oct 28, 2022

BUY
$134.21 - $153.93 $30,599 - $35,096
228 Added 13.51%
1,916 $257,000
Q2 2022

Aug 08, 2022

BUY
$137.62 - $174.96 $550 - $699
4 Added 0.24%
1,688 $259,000
Q1 2022

May 03, 2022

BUY
$131.98 - $163.75 $9,898 - $12,281
75 Added 4.66%
1,684 $273,000
Q4 2021

Jan 14, 2022

BUY
$107.43 - $135.93 $172,854 - $218,711
1,609 New
1,609 $217,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $317B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Advance Capital Management, Inc. Portfolio

Follow Advance Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advance Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advance Capital Management, Inc. with notifications on news.